11 results on '"Camille Hua"'
Search Results
2. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
- Author
-
Olivier Chosidow, Giao Do, Luigi Naldi, Emilie Sbidian, Anna Chaimani, John R. Ingram, L. Le Cleach, Camille Hua, Carolyn Hughes, Ignacio García-Doval, Catherine Droitcourt, and C. Mazaud
- Subjects
Adult ,Male ,medicine.medical_specialty ,Brodalumab ,Network Meta-Analysis ,Antibodies, Monoclonal, Humanized ,Severity of Illness Index ,Etanercept ,Placebos ,030207 dermatology & venereal diseases ,03 medical and health sciences ,Psoriatic arthritis ,0302 clinical medicine ,Psoriasis Area and Severity Index ,Internal medicine ,Ustekinumab ,Medicine ,Humans ,Psoriasis ,Pharmacology (medical) ,030212 general & internal medicine ,Molecular Targeted Therapy ,Randomized Controlled Trials as Topic ,Biological Products ,business.industry ,Tumor Necrosis Factor-alpha ,Remission Induction ,Adalimumab ,Antibodies, Monoclonal ,Middle Aged ,medicine.disease ,Infliximab ,Ixekizumab ,Methotrexate ,Guselkumab ,Treatment Outcome ,Chronic Disease ,Cytokines ,Secukinumab ,Female ,business ,Immunosuppressive Agents ,Systematic Reviews as Topic ,medicine.drug - Abstract
Background Psoriasis is an immune-mediated disease for which some people have a genetic predisposition. The condition manifests in inflammatory effects on either the skin or joints, or both, and it has a major impact on quality of life. Although there is currently no cure for psoriasis, various treatment strategies allow sustained control of disease signs and symptoms. Several randomised controlled trials (RCTs) have compared the efficacy of the different systemic treatments in psoriasis against placebo. However, the relative benefit of these treatments remains unclear due to the limited number of trials comparing them directly head to head, which is why we chose to conduct a network meta-analysis. Objectives To compare the efficacy and safety of conventional systemic agents (acitretin, ciclosporin, fumaric acid esters, methotrexate), small molecules (apremilast, tofacitinib, ponesimod), anti-TNF alpha (etanercept, infliximab, adalimumab, certolizumab), anti-IL12/23 (ustekinumab), anti-IL17 (secukinumab, ixekizumab, brodalumab), anti-IL23 (guselkumab, tildrakizumab), and other biologics (alefacept, itolizumab) for patients with moderate to severe psoriasis and to provide a ranking of these treatments according to their efficacy and safety. Search methods We searched the following databases to December 2016: the Cochrane Skin Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, and LILACS. We also searched five trials registers and the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) reports. We checked the reference lists of included and excluded studies for further references to relevant RCTs. We searched the trial results databases of a number of pharmaceutical companies and handsearched the conference proceedings of a number of dermatology meetings. Selection criteria Randomised controlled trials (RCTs) of systemic and biological treatments in adults (over 18 years of age) with moderate to severe plaque psoriasis or psoriatic arthritis whose skin had been clinically diagnosed with moderate to severe psoriasis, at any stage of treatment, in comparison to placebo or another active agent. Data collection and analysis Three groups of two review authors independently undertook study selection, data extraction, 'Risk of bias' assessment, and analyses. We synthesised the data using pair-wise and network meta-analysis (NMA) to compare the treatments of interest and rank them according to their effectiveness (as measured by the Psoriasis Area and Severity Index score (PASI) 90) and acceptability (the inverse of serious adverse effects). We assessed the certainty of the body of evidence from the NMA for the two primary outcomes, according to GRADE; we evaluated evidence as either very low, low, moderate, or high. We contacted study authors when data were unclear or missing. Main results We included 109 studies in our review (39,882 randomised participants, 68% men, all recruited from a hospital). The overall average age was 44 years; the overall mean PASI score at baseline was 20 (range: 9.5 to 39). Most of these studies were placebo controlled (67%), 23% were head-to-head studies, and 10% were multi-armed studies with both an active comparator and placebo. We have assessed all treatments listed in the objectives (19 in total). In all, 86 trials were multicentric trials (two to 231 centres). All of the trials included in this review were limited to the induction phase (assessment at less than 24 weeks after randomisation); in fact, all trials included in the network meta-analysis were measured between 12 and 16 weeks after randomisation. We assessed the majority of studies (48/109) as being at high risk of bias; 38 were assessed as at an unclear risk, and 23, low risk. Network meta-analysis at class level showed that all of the interventions (conventional systemic agents, small molecules, and biological treatments) were significantly more effective than placebo in terms of reaching PASI 90. In terms of reaching PASI 90, the biologic treatments anti-IL17, anti-IL12/23, anti-IL23, and anti-TNF alpha were significantly more effective than the small molecules and the conventional systemic agents. Small molecules were associated with a higher chance of reaching PASI 90 compared to conventional systemic agents. At drug level, in terms of reaching PASI 90, all of the anti-IL17 agents and guselkumab (an anti-IL23 drug) were significantly more effective than the anti-TNF alpha agents infliximab, adalimumab, and etanercept, but not certolizumab. Ustekinumab was superior to etanercept. No clear difference was shown between infliximab, adalimumab, and etanercept. Only one trial assessed the efficacy of infliximab in this network; thus, these results have to be interpreted with caution. Tofacitinib was significantly superior to methotrexate, and no clear difference was shown between any of the other small molecules versus conventional treatments. Network meta-analysis also showed that ixekizumab, secukinumab, brodalumab, guselkumab, certolizumab, and ustekinumab outperformed other drugs when compared to placebo in terms of reaching PASI 90: the most effective drug was ixekizumab (risk ratio (RR) 32.45, 95% confidence interval (CI) 23.61 to 44.60; Surface Under the Cumulative Ranking (SUCRA) = 94.3; high-certainty evidence), followed by secukinumab (RR 26.55, 95% CI 20.32 to 34.69; SUCRA = 86.5; high-certainty evidence), brodalumab (RR 25.45, 95% CI 18.74 to 34.57; SUCRA = 84.3; moderate-certainty evidence), guselkumab (RR 21.03, 95% CI 14.56 to 30.38; SUCRA = 77; moderate-certainty evidence), certolizumab (RR 24.58, 95% CI 3.46 to 174.73; SUCRA = 75.7; moderate-certainty evidence), and ustekinumab (RR 19.91, 95% CI 15.11 to 26.23; SUCRA = 72.6; high-certainty evidence). We found no significant difference between all of the interventions and the placebo regarding the risk of serious adverse effects (SAEs): the relative ranking strongly suggested that methotrexate was associated with the best safety profile regarding all of the SAEs (RR 0.23, 95% CI 0.05 to 0.99; SUCRA = 90.7; moderate-certainty evidence), followed by ciclosporin (RR 0.23, 95% CI 0.01 to 5.10; SUCRA = 78.2; very low-certainty evidence), certolizumab (RR 0.49, 95% CI 0.10 to 2.36; SUCRA = 70.9; moderate-certainty evidence), infliximab (RR 0.56, 95% CI 0.10 to 3.00; SUCRA = 64.4; very low-certainty evidence), alefacept (RR 0.72, 95% CI 0.34 to 1.55; SUCRA = 62.6; low-certainty evidence), and fumaric acid esters (RR 0.77, 95% CI 0.30 to 1.99; SUCRA = 57.7; very low-certainty evidence). Major adverse cardiac events, serious infections, or malignancies were reported in both the placebo and intervention groups. Nevertheless, the SAEs analyses were based on a very low number of events with low to very low certainty for just over half of the treatment estimates in total, moderate for the others. Thus, the results have to be considered with caution. Considering both efficacy (PASI 90 outcome) and acceptability (SAEs outcome), highly effective treatments also had more SAEs compared to the other treatments, and ustekinumab, infliximab, and certolizumab appeared to have the better trade-off between efficacy and acceptability. Regarding the other efficacy outcomes, PASI 75 and Physician Global Assessment (PGA) 0/1, the results were very similar to the results for PASI 90. Information on quality of life was often poorly reported and was absent for a third of the interventions. Authors' conclusions Our review shows that compared to placebo, the biologics ixekizumab, secukinumab, brodalumab, guselkumab, certolizumab, and ustekinumab are the best choices for achieving PASI 90 in people with moderate to severe psoriasis on the basis of moderate- to high-certainty evidence. At class level, the biologic treatments anti-IL17, anti-IL12/23, anti-IL23, and anti-TNF alpha were significantly more effective than the small molecules and the conventional systemic agents, too. This NMA evidence is limited to induction therapy (outcomes were measured between 12 to 16 weeks after randomisation) and is not sufficiently relevant for a chronic disease. Moreover, low numbers of studies were found for some of the interventions, and the young age (mean age of 44 years) and high level of disease severity (PASI 20 at baseline) may not be typical of patients seen in daily clinical practice. Another major concern is that short-term trials provide scanty and sometimes poorly reported safety data and thus do not provide useful evidence to create a reliable risk profile of treatments. Indeed, we found no significant difference in the assessed interventions and placebo in terms of SAEs. Methotrexate appeared to have the best safety profile, but as the evidence was of very low to moderate quality, we cannot be sure of the ranking. In order to provide long-term information on the safety of the treatments included in this review, it will be necessary to evaluate non-randomised studies and postmarketing reports released from regulatory agencies as well. In terms of future research, randomised trials comparing directly active agents are necessary once high-quality evidence of benefit against placebo is established, including head-to-head trials amongst and between conventional systemic and small molecules, and between biological agents (anti-IL17 versus anti-IL23, anti-IL23 versus anti-IL12/23, anti-TNF alpha versus anti-IL12/23). Future trials should also undertake systematic subgroup analyses (e.g. assessing biological-naive patients, baseline psoriasis severity, presence of psoriatic arthritis, etc.). Finally, outcome measure harmonisation is needed in psoriasis trials, and researchers should look at the medium- and long-term benefit and safety of the interventions and the comparative safety of different agents.
- Published
- 2021
3. Impact of systemic to topical steroids switch on the outcome of drug reaction with eosinophilia and systemic symptoms (DRESS): A monocenter retrospective study of 20 cases
- Author
-
C. Brin, N. de Prost, Charlotte Bernigaud, T.-A. Duong, Saskia Ingen-Housz-Oro, O. Gaudin, A. Colin, Pierre Wolkenstein, Olivier Chosidow, and Camille Hua
- Subjects
Adult ,Male ,medicine.medical_specialty ,Administration, Topical ,Dermatology ,Drug reaction with eosinophilia and systemic symptoms ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Epidemiology ,Eosinophilia ,medicine ,Retrospective analysis ,Humans ,Relapse risk ,Retrospective Studies ,business.industry ,Dermatology department ,Retrospective cohort study ,Middle Aged ,medicine.disease ,Treatment Outcome ,Treatment modality ,Drug Hypersensitivity Syndrome ,Severity Criteria ,Female ,Steroids ,business - Abstract
Background There is no consensus on the treatment of drug reaction with eosinophilia and systemic symptoms (DRESS). At our center, systemic steroids (SS) are used for severe cases while topical steroids (TS) are used for mild and moderate forms. Objectives To investigate the short-term outcome for patients with DRESS receiving SS as first-line therapy before being transferred to our department and then switched to TS after admission. Methods A retrospective monocenter study in DRESS patients (RegiSCAR score ≥ 4) transferred to our dermatology department from a different setting between 07/2012 and 06/2018 and who had received SS before being transferred. Epidemiological, clinical and laboratory data were collected, as well as details of treatment modalities and outcome. Results Twenty patients were included. On admission to our department, 4 were assessed as having severe DRESS and continued on SS, while 16 were assessed as mild/moderate DRESS and were switched to TS. Among these 16 patients, the outcome on TS was favorable for 12 and quickly unfavorable for 4, who had to be switched back to SS. Retrospective analysis of the initial data (before transfer) showed that these 4 patients had previously had a greater number of severity criteria than the other 12. Conclusion Caution is needed not only when deciding to initiate SS in DRESS but also on withdrawal of these drugs. Our series suggests that when SS are used as first-line therapy in DRESS patients with initial severity criteria, they should not be withdrawn quickly for a switch to TS, even where progression appears favorable, due to the risk of relapse.
- Published
- 2020
4. Interventions for necrotizing soft tissue infections in adults
- Author
-
Nicolas de Prost, Patricia Jabre, Camille Hua, L. Le Cleach, Emilie Sbidian, Olivier Chosidow, Carolyn Hughes, and Romain Bosc
- Subjects
Adult ,Male ,Medicine General & Introductory Medical Sciences ,medicine.medical_specialty ,Critical Care ,Moxifloxacin ,030230 surgery ,Placebo ,Amoxicillin-Potassium Clavulanate Combination ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,CD28 Antigens ,law ,Internal medicine ,Intensive care ,medicine ,Adjuvant therapy ,Humans ,Pharmacology (medical) ,030212 general & internal medicine ,Adverse effect ,Randomized Controlled Trials as Topic ,business.industry ,Mortality rate ,Soft Tissue Infections ,Immunoglobulins, Intravenous ,Middle Aged ,Intensive care unit ,Surgery ,Anti-Bacterial Agents ,Debridement ,Relative risk ,Female ,business ,Fluoroquinolones - Abstract
BACKGROUND: Necrotizing soft tissue infections (NSTIs) are severe and rapidly spreading soft tissue infections of the subcutaneous tissue, fascia, or muscle, which are mostly caused by bacteria. Associated rates of mortality and morbidity are high, with the former estimated at around 23%, and disability, sequelae, and limb loss occurring in 15% of patients. Standard management includes intravenous empiric antimicrobial therapy, early surgical debridement of necrotic tissues, intensive care support, and adjuvant therapies such as intravenous immunoglobulin (IVIG). OBJECTIVES: To assess the effects of medical and surgical treatments for necrotizing soft tissue infections (NSTIs) in adults in hospital settings. SEARCH METHODS: We searched the following databases up to April 2018: the Cochrane Skin Group Specialised Register, CENTRAL, MEDLINE, Embase, and LILACS. We also searched five trials registers, pharmaceutical company trial results databases, and the US Food and Drug Administration and the European Medicines Agency websites. We checked the reference lists of included studies and reviews for further references to relevant randomised controlled trials (RCTs). SELECTION CRITERIA: RCTs conducted in hospital settings, that evaluated any medical or surgical treatment for adults with NSTI were eligible for inclusion. Eligible medical treatments included 1) comparisons between different antimicrobials or with placebo; 2) adjuvant therapies such as intravenous immunoglobulin (IGIV) therapy compared with placebo; no treatment; or other adjuvant therapies. Eligible surgical treatments included surgical debridement compared with amputation, immediate versus delayed intervention, or comparisons of number of interventions. RCTs of hyperbaric oxygen (HBO) therapy for NSTI were ineligible because HBO is the focus of another Cochrane Review. DATA COLLECTION AND ANALYSIS: We used standard methodological procedures expected by Cochrane. The primary outcome measures were 1) mortality within 30 days, and 2) proportion of participants who experience a serious adverse event. Secondary outcomes were 1) survival time, and 2) assessment of long‐term morbidity. We used GRADE to assess the quality of the evidence for each outcome. MAIN RESULTS: We included three trials randomising 197 participants (62% men) who had a mean age of 55 years. One trial compared two antibiotic treatments, and two trials compared adjuvant therapies with placebo. In all trials, participants concomitantly received standard interventions, such as intravenous empiric antimicrobial therapy, surgical debridement of necrotic tissues, intensive care support, and adjuvant therapies. All trials were at risk of attrition bias and one trial was not blinded. Moxifloxacin versus amoxicillin‐clavulanate One trial included 54 participants who had a NSTI; it compared a third‐generation quinolone, moxifloxacin, at a dose of 400 mg given once daily, against a penicillin, amoxicillin‐clavulanate, at a dose of 3 g given three times daily for at least three days, followed by 1.5 g three times daily. Duration of treatment varied from 7 to 21 days. We are uncertain of the effects of these treatments on mortality within 30 days (risk ratio (RR) 3.00, 95% confidence interval (CI) 0.39 to 23.07) and serious adverse events at 28 days (RR 0.63, 95% CI 0.30 to 1.31) because the quality of the evidence is very low. AB103 versus placebo One trial of 43 randomised participants compared two doses, 0.5 mg/kg and 0.25 mg/kg, of an adjuvant drug, a CD28 antagonist receptor (AB103), with placebo. Treatment was given via infusion pump for 10 minutes before, after, or during surgery within six hours after the diagnosis of NSTI. We are uncertain of the effects of AB103 on mortality rate within 30 days (RR of 0.34, 95% CI 0.05 to 2.16) and serious adverse events measured at 28 days (RR 1.49, 95% CI 0.52 to 4.27) because the quality of the evidence is very low. Intravenous immunoglobulin (IVIG) versus placebo One trial of 100 randomised participants assessed IVIG as an adjuvant drug, given at a dose of 25 g/day, compared with placebo, given for three consecutive days. There may be no clear difference between IVIG and placebo in terms of mortality within 30 days (RR 1.17, 95% CI 0.42 to 3.23) (low‐certainty evidence), nor serious adverse events experienced in the intensive care unit (ICU) (RR 0.73 CI 95% 0.32 to 1.65) (low‐certainty evidence). Serious adverse events were only described in one RCT (the IVIG versus placebo trial) and included acute kidney injury, allergic reactions, aseptic meningitis syndrome, haemolytic anaemia, thrombi, and transmissible agents. Only one trial reported assessment of long‐term morbidity, but the outcome was not defined in the way we prespecified in our protocol. The trial used the Short Form Health Survey (SF36). Data on survival time were provided upon request for the trials comparing amoxicillin‐clavulanate versus moxifloxacin and IVIG versus placebo. However, even with data provided, it was not possible to perform survival analysis. AUTHORS' CONCLUSIONS: We found very little evidence on the effects of medical and surgical treatments for NSTI. We cannot draw conclusions regarding the relative effects of any of the interventions on 30‐day mortality or serious adverse events due to the very low quality of the evidence. The quality of the evidence is limited by the very small number of trials, the small sample sizes, and the risks of bias in the included trials. It is important for future trials to clearly define their inclusion criteria, which will help with the applicability of future trial results to a real‐life population. Management of NSTI participants (critically‐ill participants) is complex, involving multiple interventions; thus, observational studies and prospective registries might be a better foundation for future research, which should assess empiric antimicrobial therapy, as well as surgical debridement, along with the placebo‐controlled comparison of adjuvant therapy. Key outcomes to assess include mortality (in the acute phase of the condition) and long‐term functional outcomes, e.g. quality of life (in the chronic phase).
- Published
- 2018
5. Association Between Severe Acute Contact Dermatitis Due to Nigella sativa Oil and Epidermal Apoptosis
- Author
-
A. Jannic, O. Gaudin, Pierre Wolkenstein, Elena Giménez-Arnau, Feyrouz Toukal, Haudrey Assier, Olivier Chosidow, Saskia Ingen-Housz-Oro, Camille Hua, Nicolas Ortonne, Service de dermatologie [Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Institut de Chimie de Strasbourg, Université de Strasbourg (UNISTRA)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), and Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC)
- Subjects
medicine.medical_specialty ,Apoptosis ,Dermatology ,Dermatitis, Contact ,Severity of Illness Index ,030207 dermatology & venereal diseases ,03 medical and health sciences ,chemistry.chemical_compound ,Basal (phylogenetics) ,Young Adult ,0302 clinical medicine ,Dermis ,Severity of illness ,medicine ,Humans ,Plant Oils ,[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology ,Thymoquinone ,Retrospective Studies ,business.industry ,Brief Report ,Middle Aged ,Patch Tests ,medicine.disease ,Pathophysiology ,Toxic epidermal necrolysis ,3. Good health ,medicine.anatomical_structure ,chemistry ,030220 oncology & carcinogenesis ,Acute Disease ,Female ,Epidermis ,business ,Contact dermatitis ,[SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology ,Case series - Abstract
International audience; Importance Nigella sativa oil (NSO) is widely used for cosmetic and culinary purposes. Cases of severe acute contact dermatitis due to NSO are poorly described, with no histologic description.Objectives To describe the clinical and histologic features of severe acute contact dermatitis due to NSO and investigate the components responsible for such eruptions.Design, Setting, and Participants A case series study of 3 patients with contact dermatitis admitted to the dermatology department between August 21, 2009, and February 19, 2017, was conducted. All patients had been referred to the dermatology department for acute contact dermatitis due to NSO and had patch tests performed.Main Outcomes and Measures Clinical and histologic features of the cutaneous eruptions, length of hospital stay, chemical analysis of NSO, and results of patch tests.Results Three patients (3 women; median age, 27 years [range, 20-47 years]) were included in the case series. All patients had polymorphic skin lesions spreading beyond the area of NSO application: typical and atypical targets, patches with central blisters, erythematous or purpuric plaques with a positive Nikolsky sign mimicking Stevens-Johnson syndrome, or toxic epidermal necrolysis. Two patients had pustules. They had severe impairment, with more than 15% skin detachment and fever. The results of skin biopsies showed epidermal apoptosis characterized by vacuolar alteration of the basal layer, keratinocyte apoptosis, and a moderate perivascular infiltrate of lymphocytes in the dermis. The results of patch tests using the patients’ NSO were all positive. The results of gas chromatography combined with mass spectrometry performed on the NSO of 1 patient identified several constituent substances, mainly terpenes, thymoquinone, linoleic acid, and fatty acids.Conclusions and Relevance These cases suggest that acute contact dermatitis due to NSO may induce topically triggered epidermal apoptosis, previously described as the concept of acute syndrome of apoptotic pan epidermolysis. Thymoquinone and p-cymene may be the main agents involved in the pathophysiologic characteristics of this acute contact dermatitis. Clinicians should be aware of such severe reactions to NSO and report these cases to pharmacovigilance authorities.
- Published
- 2018
6. Primary cutaneous mucormycosis as a complication of erosive dermatitis: two cases
- Author
-
Dragos Popescu, Camille Hua, Françoise Botterel, Devy Lu, Berline Sigha, Françoise Foulet, Olivier Ellrodt, Nicolas Ortonne, A. Servy, Olivier Chosidow, Nicolas de Prost, Saskia Ingen-Housz-Oro, and Pierre Wolkenstein
- Subjects
0301 basic medicine ,Male ,medicine.medical_specialty ,Antifungal Agents ,030106 microbiology ,MEDLINE ,Dermatology ,Risk Assessment ,Severity of Illness Index ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Fatal Outcome ,Severity of illness ,Combined Modality Therapy ,Medicine ,Dermatomycoses ,Humans ,Mucormycosis ,030212 general & internal medicine ,Young adult ,Cutaneous mucormycosis ,business.industry ,Middle Aged ,Debridement ,Stevens-Johnson Syndrome ,Superinfection ,Dermatitis, Irritant ,Female ,Immunocompetence ,Complication ,business ,Risk assessment - Published
- 2017
7. Cyclosporine for Epidermal Necrolysis: Absence of Beneficial Effect in a Retrospective Cohort of 174 Patients-Exposed/Unexposed and Propensity Score-Matched Analyses
- Author
-
Camille Hua, Tu Anh Duong, A. Colin, Laurence Fardet, L. Le Cleach, Emilie Sbidian, Olivier Chosidow, Pierre Wolkenstein, O. Gaudin, Claire Hotz, Florence Poizeau, Ouidad Zehou, Nicolas de Prost, Saskia Ingen-Housz-Oro, Bénédicte Lebrun-Vignes, CHU Pontchaillou [Rennes], Service de dermatologie [Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service de Dermatologie, Hopital Mondor, Assistance Publique des Hôpitaux de Paris, Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Assistance Publique des Hôpitaux de Paris, Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), CHU Henri Mondor, Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), PRES Université Paris-Est, Service de réanimation médicale, Centre Régional de Pharmacovigilance (CRPV), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor, Département de dermatologie, hôpital Henri Mondor, Epidemiology in Dermatology and Evaluation in Therapeutics (EpiDermE), and VO, alexandra
- Subjects
0301 basic medicine ,Adult ,Male ,medicine.medical_specialty ,Randomization ,Palliative care ,Dermatology ,Biochemistry ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Re-Epithelialization ,Internal medicine ,Epidemiology ,medicine ,Humans ,Treatment Failure ,Propensity Score ,Molecular Biology ,Survival analysis ,ComputingMilieux_MISCELLANEOUS ,Retrospective Studies ,Skin ,Body surface area ,business.industry ,Palliative Care ,Retrospective cohort study ,Cell Biology ,[SDV.MHEP.DERM] Life Sciences [q-bio]/Human health and pathology/Dermatology ,Acute Kidney Injury ,Middle Aged ,medicine.disease ,Survival Analysis ,Toxic epidermal necrolysis ,030104 developmental biology ,Stevens-Johnson Syndrome ,Propensity score matching ,Cyclosporine ,Disease Progression ,Female ,business ,[SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology ,Immunosuppressive Agents - Abstract
Cyclosporine has shown promising results for mortality in patients with Stevens-Johnson syndrome/toxic epidermal necrolysis. However, available studies included only a small number of patients and did not include a validated and homogenous control group. We present the results from a retrospective monocentric study including 174 patients with Stevens-Johnson syndrome/toxic epidermal necrolysis during 2005–2016. Among them, 95 received cyclosporine (3 mg/kg/day) plus supportive care, and 79 received supportive care only. Both a traditional exposed/unexposed method and a propensity score-matching method were used to compare the progression of skin detachment between day 0 and day 5, the proportion of patients with cutaneous re-epithelialization starting on day 5 or mucosal re-epithelialization on day 10, the duration of progression, and the number of deaths between the two groups. None of these outcomes significantly favored cyclosporine, either by the exposed/unexposed method or the propensity score method. Acute renal failure affected more patients receiving cyclosporine (P = 0.05). Overall, the results of this epidemiological study did not show a beneficial effect of cyclosporine in patients with Stevens-Johnson syndrome/toxic epidermal necrolysis. They are discordant with those previously published. The large number of patients and the use of a propensity score method provide valuable insights. The main limitation of the study is the lack of randomization.
- Published
- 2017
8. Locally Aggressive Trichoblastic Tumours (Low-grade Trichoblastic Carcinomas): Clinicopathological Analysis and Follow-up
- Author
-
Maxime Battistella, Nicole Basset-Seguin, Amélie Osio, Camille Hua, C. Velter, Bernard Cribier, and Céleste Lebbé
- Subjects
Adult ,Male ,Oncology ,medicine.medical_specialty ,Skin Neoplasms ,Time Factors ,Treatment outcome ,MEDLINE ,Dermatology ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Text mining ,Terminology as Topic ,Internal medicine ,Biomarkers, Tumor ,lcsh:Dermatology ,medicine ,Humans ,Hardware_ARITHMETICANDLOGICSTRUCTURES ,Hardware_REGISTER-TRANSFER-LEVELIMPLEMENTATION ,Aged ,Retrospective Studies ,Aged, 80 and over ,Neoplasm Grading ,business.industry ,Carcinoma ,Follow up studies ,Retrospective cohort study ,General Medicine ,Middle Aged ,lcsh:RL1-803 ,Treatment Outcome ,030220 oncology & carcinogenesis ,Female ,Hardware_CONTROLSTRUCTURESANDMICROPROGRAMMING ,business ,Hair Follicle ,Follow-Up Studies - Published
- 2018
9. Sirolimus improves pain in NF1 patients with severe plexiform neurofibromas
- Author
-
Veronique Minard-Colin, Dominique Hamel-Teillac, Stéphane Ducassou, Ouidad Zehou, Pierre Wolkenstein, Camille Hua, and Laurence Valeyrie-Allanore
- Subjects
Oncology ,Drug ,Male ,medicine.medical_specialty ,Neurofibromatosis 1 ,Adolescent ,media_common.quotation_subject ,Drug Administration Schedule ,Plexiform neurofibroma ,Internal medicine ,medicine ,Neurofibroma ,Humans ,Neurofibromatosis ,Cooperative Behavior ,Child ,PI3K/AKT/mTOR pathway ,media_common ,Pain Measurement ,Neurofibroma, Plexiform ,Sirolimus ,Dose-Response Relationship, Drug ,business.industry ,Chronic pain ,medicine.disease ,Surgery ,Abdominal Neoplasms ,Pediatrics, Perinatology and Child Health ,Nociceptor ,Female ,Interdisciplinary Communication ,Chronic Pain ,business ,medicine.drug ,Follow-Up Studies - Abstract
Plexiform neurofibromas (PNs) are common and potentially debilitating complications of neurofibromatosis 1 (NF1). These benign nerve-sheath tumors are associated with significant pain and morbidity because they compress vital structures. The mammalian target of rapamycin (mTOR) pathway is a major mediator involved in tumor growth in NF1. We present 3 cases of patients with NF1, aged 8, 16, and 17 years, followed for inoperable and symptomatic PNs; patients received sirolimus for life-threatening and painful neurofibromas after multidisciplinary consultation. Epidemiologic, clinical, and radiologic data were retrospectively collected. The volume of PNs did not differ between baseline and 12-month follow-up and pain was alleviated, with withdrawal of analgesics in 2 cases at 6 months, and significantly decreased for the third case. Sirolimus for inoperable symptomatic PNs in patients with NF1 permitted stabilization of mass and produced unpredictable and important alleviation of pain in all cases with good tolerance. This treatment was proposed in extreme cases, in absence of therapeutic alternatives, after multidisciplinary consensus. The mTOR pathway may be both a major mediator of NF1 tumor growth and regulator of nociceptor sensitivity. mTOR inhibitors clinically used as anticancer and immunosuppressant drugs could be a potential treatment of chronic pain.
- Published
- 2014
10. Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab
- Author
-
Emilie Lanoy, Roxane Viollet, Camille Hua, Gorana Tomasic, Emilie Routier, H. Cazenave, Lise Boussemart, Caroline Robert, Naima Benannoune, Stéphane Champiat, Christine Mateus, Jean-Charles Soria, Séverine Roy, M. Thomas, M. Texier, and Celine Boutros
- Subjects
Adult ,Male ,medicine.medical_specialty ,Skin Neoplasms ,Time Factors ,Vitiligo ,Antineoplastic Agents ,Context (language use) ,Dermatology ,Pembrolizumab ,Antibodies, Monoclonal, Humanized ,Young Adult ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Humans ,Prospective Studies ,Neoplasm Metastasis ,skin and connective tissue diseases ,Prospective cohort study ,Melanoma ,Survival rate ,Survival analysis ,Aged ,integumentary system ,business.industry ,Middle Aged ,medicine.disease ,Surgery ,Survival Rate ,Treatment Outcome ,030220 oncology & carcinogenesis ,Female ,business ,Progressive disease ,Follow-Up Studies - Abstract
Importance Vitiligo is an autoimmune skin disorder that reacts against melanocytes. The association of vitiligo with tumor response in patients with melanoma who undergo immunotherapy has been reported but is still controversial. Objective To prospectively evaluate the appearance of vitiligo in patients receiving pembrolizumab, a monoclonal antibody directed against the programmed death cell receptor. Design, Setting, and Participants This prospective observational study was conducted from January 1, 2012, through September 24, 2013, in a single tertiary care hospital with a unit dedicated to patients with melanoma. Sixty-seven patients with metastatic melanoma who received pembrolizumab treatment in the context of a phase 1 study were included and screened for the emergence of vitiligo. Data were collected from January 1, 2012, to February 28, 2014, and analyzed from February through December 2014. Main Outcomes and Measures Objective tumor response with regard to the occurrence of vitiligo in patients receiving pembrolizumab therapy. Correlation between vitiligo occurrence and overall survival was also estimated using the Kaplan-Meier product-limit method and compared with a log-rank test. To prevent guarantee- or lead-time bias, a landmark analysis approach after 12, 16, and 20 weeks of treatment was retained. Results Of the 67 patients included in the study, 17 (25%) developed vitiligo during pembrolizumab treatment and 50 (75%) did not. An objective (complete or partial) response to treatment was associated with a higher occurrence of vitiligo (12 of 17 [71%] vs 14 of 50 [28%]; P = .002). The time to onset of vitiligo ranged from 52 to 453 (median, 126) days from the start of treatment. Of the 17 patients with vitiligo, 3 (18%) had a complete response, 9 (53%) had a partial response, 3 (18%) had stable disease, and 2 (12%) had progressive disease at the final follow-up. All the patients treated with pembrolizumab who developed vitiligo were alive at the time of analysis, with a median follow-up of 441 days. Conclusions and Relevance Vitiligo, a clinically visible immune-related adverse event could be associated with clinical benefit in the context of pembrolizumab treatment.
- Published
- 2016
11. Prognostic factors in necrotizing soft-tissue infections (NSTI): A cohort study
- Author
-
Jean Winoc Decousser, Nicolas de Prost, Pierre Wolkenstein, Emilie Sbidian, Alain Rahmouni, Roland Amathieu, Laurence Valeyrie-Allanore, Romain Bosc, Olivier Chosidow, Camille Hua, Christian Brun-Buisson, and François Hemery
- Subjects
Male ,medicine.medical_specialty ,Critical Care ,Comorbidity ,Kaplan-Meier Estimate ,Dermatology ,Risk Assessment ,Severity of Illness Index ,Time-to-Treatment ,Cohort Studies ,Tertiary Care Centers ,Necrosis ,Interquartile range ,Internal medicine ,Epidemiology ,Severity of illness ,Humans ,Medicine ,Fasciitis, Necrotizing ,Hospital Mortality ,Aged ,Proportional Hazards Models ,Retrospective Studies ,Analysis of Variance ,business.industry ,Proportional hazards model ,Soft Tissue Infections ,Hazard ratio ,Age Factors ,Retrospective cohort study ,Length of Stay ,Middle Aged ,Survival Analysis ,Surgery ,Hospitalization ,Intensive Care Units ,Treatment Outcome ,Multivariate Analysis ,Cohort ,Female ,business ,Follow-Up Studies ,Cohort study - Abstract
Background Necrotizing soft-tissue infection (NSTI) is uncommon but life-threatening. A recent meta-analysis estimated the overall mortality at 23.5%. Objective We sought to identify risk factors associated with mortality in a cohort of patients with NSTI in a tertiary care center. Methods We identified 512 patients with NSTI between 1996 and 2012 in the national hospital database Program for Medicalization of Information Systems and examined risk factors of mortality with NSTI by univariate and multivariate analysis. Results We included 109 patients with a confirmed diagnosis of NSTI; 31 (28%) died at a median follow-up of 274 days (range 2-6135 days). On multivariate analysis, independent risk factors of mortality were age older than 75 years (hazard ratio [HR] 4.4, 95% confidence interval [CI] 1.8-10.3), multifocal NSTI (HR 5.9, 95% CI 1.9-18.5), severe peripheral vascular disease (HR 5.1, 95% CI 1.5-17.0), hospital-acquired infection (HR 3.9, 95% CI 1.4-10.7), severe sepsis (HR 7.4, 95% CI 1.7-33.1), and septic shock on hospital admission (HR 13.9, 95% CI 3.8-50.4). Limitations This was a retrospective cohort, which disallows a precise record of the delay between diagnosis and surgery. Conclusion Our findings for this robust cohort of patients with a definite diagnosis of NSTI could help clinicians stratify NSTI severity at clinical course onset.
- Published
- 2015
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.